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Objective: Buruli ulcer disease (BU), caused by Mycobacterium ulcerans, is endemic in many regions of Africa and 
causes substantial physical disability. Surgical resection, currently the mainstay of clinical management of BU, is 
impractical in many endemic areas. Therefore, the study was undertaken to evaluate an antibiotic regimen for med- 
ical management of BU. 
Methods: A randomized, placebo-controlled pilot study of dapsone plus rifampin versus placebo was conducted. 
Results: Forty-one participants were recruited in a BU-endemic zone of C&e d’Ivoire. Thirty persons completed 
the 2-month trial: 15 were treated with placebo and 15 with dapsone and rifampin. On blinded evaluation of 
photographs of the ulcers, clinicians with experience examining BU judged that 82% of ulcers in the treatment 
group improved compared with 75% in the placebo group (P=OSl). The median change in ulcer size was a 
decrease of 14.0 cm2 in the treatment group and a decrease of 2.5 cm2 in the placebo group (P=O.O2), but initial ulcer 
sizes were larger in the treatment group (median 26.2 cm2) compared with the placebo group (median 4.8 cm2) 
(P=O.O4). 
Conclusions: Results of this study indicate that larger studies of antimycobacterial therapy of BU are warranted 
and can be successfully undertaken. 
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Mycobacterium ulcerans, a slow-growing, toxin- 
producing bacterium, causes characteristic skin lesions. 
These lesions are commonly called Buruli ulcers (BU), 
after the highly endemic area of Uganda where the first 
large-scale investigations of the disease took p1ace.l 
Although the ulcers are usually self-limited, healing 
spontaneously over a period of months to several 
years, they may lead to severe joint contractures, 
lymphedema, and disfigurement. 
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Buruli ulcer disease appears to have increased its 
range in Africa over the past two decades. The earliest 
reports of endemic foci in Africa came from Uganda 
and Zaire in the 195Os.l Since the 1970s West African 
countries including Nigeria, Benin, Ghana, Liberia, and 
C&e d’Ivoire,2-6 have experienced an increase in 
reported cases. From 1987 to 1991, C&e d’Ivoire experi- 
enced a 3-fold increase in reported cases, and preva- 
lence reached 16% in some villages.6 Despite widening 
geographic distribution, cases tend to be localized to 
specific regions within affected countries. 
The pathophysiology of clinical disease has been 
well described.7-9 However, few effective or practical 
treatments exist for BU. Debridement of necrotic tissue, 
combined with skin grafting, has long been used for 
large BU lesions with variable results; recurrences 
and extension are common. Surgical excision of pre- 
ulcerative lesions or small ulcers is curative.lO However, 
this approach is impractical for many affected individ- 
uals, both because early lesions are difficult to identify 
and because many patients live in remote areas with 
rudimentary health care. Because M. ukerans requires 
a temperature of 33°C for growth in the laboratory, 
direct application of heat to speed healing has been rec- 
ommended, but results of clinical trials have been 
inconclusive.11~12 
Mycobacterium ulcerans isolates are susceptible 
in vitro to many antibiotic agents,i3-l5 but only one con- 
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trolled clinical trial of antibiotic therapy for BU has 
been reported. Revill and colleagues found no effect of 
treatment of BU with clofazimine in 1973.16 However, 
many mycobacterial infections require therapy with 
combinations of antibiotic agents. Such therapy pro- 
vides increased antimycobacterial activity and decreases 
the likelihood of failure because of drug resistance. 
Therefore, a prospective, placebo-controlled pilot study 
of therapy of BU with a combination of rifampin and 
dapsone was undertaken. These agents were selected 
for the present trial because both have shown labora- 
tory evidence of activity against M. ulceruns and their 
safety has been demonstrated through years of use in 
developing countries in the treatment of tuberculosis 
and leprosy. 
MATERIALS AND METHODS 
Enrollment 
From March 3 to April 4, 1994, leaders of all villages 
in a region northeast of Daloa in southwestern 
C&e d’Ivoire near the Lobe-River, extending to the 
Figure 1. Photograph of a large Buruli ulcer on the lateral 
aspect of the left knee at enrollment. Name indicates village 
where examination was performed. 
Sassandra River, were interviewed and asked to help 
identify cases of BU. This geographic area is known to 
be endemic for BU from a previous study and from 
ongoing case ascertainment performed by district 
health officials.6 Entry criteria into the study included 
that the person met the clinical case definition for 
BU; had no known tuberculosis, leprosy, human immuno- 
deficiency virus infection, or hepatic insufficiency 
(established by verbal query); was not pregnant or 
breastfeeding; was capable of taking oral medication; 
and was 4 years of age or older. 
The study was approved by the Institutional Review 
Board of the Centers for Disease Control and Prevention 
(CDC) and by the Ministry of Health of Cote d’Ivoire. 
Informed consent, consisting of an explanation of poten- 
tial benefits, risks and an assurance of patient confiden- 
tiality, was obtained from participants who were aged 18 
years or older. Consent was obtained from a parent or 
guardian if the participant was younger than 18. 
Case definitions 
Buruli ulcer was defined as the presence of a painless 
or minimally painful cutaneous ulcer with undermined 
Figure 2. Photograph of the ulcer shown in Figure 1 after 70 
days of treatment with dapsone and rifampin. Name indicates 
village where examination was performed. 
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margins (Figure 1). A single lesion was chosen as a 
“study ulcer” in each patient. In the case of multiple 
ulcers, the largest lesion was chosen as the study ulcer. 
Skin Biopsies. A 4- or 6-mm punch biopsy was obtained 
from each study participant at the recessed margin of 
the undermined area of the ulcer, identified by probing 
the lateral extent of the ulcer base with a cotton-tipped 
swab. 
Laboratory examinations 
Histologic examination was performed at the CDC and 
the Armed Forces Institute of Pathology after the speci- 
mens were stained with hematoxylin-eosin, Ziehl- 
Neelsen, Gomori’s methenamine silver, and Brown- 
Hopps stains. At the Belgian Institute of Tropical Medi- 
cine, specimens were prepared for culture by macera- 
tion and decontamination. They were then placed 
on Lowenstein-Jensen medium, 1% Ogawa egg yolk 
medium and Ogawa supplemented with mycobactin. 
All inoculated media were incubated for up to 12 
months at 33°C and observed weekly. 
Treatment 
Following enrollment and biopsy, participants were ran- 
domized by lot to one of two groups. The first group 
received a combination of dapsone (1.0-1.5 mg/kg/d) 
and rifampin (lo-20 mg/kg/d), whereas the second 
group received a placebo identical in appearance to 
dapsone. No placebo for rifampin was given. The inves- 
tigators were not blinded to treatment status. Partici- 
pants in both groups received supportive local ulcer 
care consisting of cleansing and nonsurgical debride- 
ment. Both groups received treatment for 2 months. 
Follow-up 
Subjects were scheduled for follow-up appointments at 
l- to 2-week intervals for the first month. Each follow- 
up visit included an evaluation of compliance with med- 
ication by patient query and by pill count. Measurements 
of the study lesion were taken at enrollment and at 
each follow-up visit. The lesions were generally round 
to oval, and ulcer dimensions were obtained by multi- 
plying the greatest perpendicular cross diameters of the 
study lesion. These diameters were approximated for 
ulcers having more complex contours. Photographs 
of the study lesions were taken at enrollment and 
repeated after 1 and 2 months of participation in the 
study. A ruler and a label with the date and participant 
identification number were placed next to the lesion 
and included in the photographs. 
Analysis 
Analysis was performed using data from participants of 
both groups who demonstrated adequate compliance. 
Adequate compliance was defined as evidence, through 
patient or guardian query and pill count (with packets 
and containers present), that at least 75% of the dap- 
sone and dapsone-placebo prescribed for the 2-month 
period had been taken by the patient. Compliance with 
dapsone and dapsone-placebo was assessed to facilitate 
comparison between the two groups, assuming that 
compliance with dapsone in the treatment group mir- 
rored compliance with rifampin. Determination of clin- 
ical evolution of the study ulcers was made by 
comparing photographs of the lesions at enrollment 
and after 2 months of treatment. Photographs were 
examined by two infectious disease specialists with sub- 
stantial experience examining BU in Africa (CRH, 
BJM); these specialists were blinded to the treatment 
status of study participants in the photographs. The spe- 
cialists scored the paired photographs as “worse,” 
“unchanged,” or “improved.“The scores were combined 
and the responses of the two treatment groups were 
compared by chi-squared test. The Wilcoxon two- 
sample test was used to compare the two groups, based 
on change in size of the ulcers at entry compared with 
size after 2 months of treatment. All data were entered 
and analyzed using Epi-Info, Version 6.02.17 
Table 1. Comparison of study participants by inclusion status and treatment group, Buruli ulcer treatment trial 
Characteristic of 
wow 
Participants 
Excluded Analyzed 
(rbll) (n=30) P=Value 
Group 
Treatment* Placebo 
(n=lS) (n=15) P-Value 
Median size of study 
lesion (cm*) 
Range 
Median (y) age 
Range 
Active:Placebo+ 
Gender distribution 
(M:F) 
5.0 14.0 
1.5-120 0.25-280 
11 9 
3-29 5-60 
5:6 15:15 
6:5 18:12 
P=O.73 
P=O. 18 
P=O.80 
P=l .oo 
26.2 4.8 
0.25-280 0.25-57.5 
13 IO 
5-60 5-60 
NA NA 
II:4 7~8 
P=O.O4 
P=O.86 
NA 
P=O.12 
*Dapsone and rifampin therapy; *treatment group ratio. 
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RESULTS 
Forty-one patients fulfilled the entry criteria and case 
definition (Table 1). Seventeen (41.5%) were female 
and 24 (58.5%) were male. Ten of the 41 patients were 
lost to follow-up and were excluded from the analysis. 
One patient was excluded because she became preg- 
nant. There were no significant differences based on 
initial size of ulcer, treatment status (active vs. placebo), 
gender, or age between participants who were excluded 
and those not excluded from the final analysis. The 
initial median size of ulcers was larger in the active 
treatment group compared with the placebo group for 
evaluable participants (26.2 cm2 [range 0.25-2801 vs. 4.8 
cm2 [range 0.25-57.51, P=O.O4). No adverse effects of 
treatment were reported when patients were asked 
specifically about potential side effects of the medica- 
tion. Generally, patients from the villages were more 
likely to comply with the follow-up than the patients 
from the smaller and more peripheral “campements” 
(temporary work camps). 
Six of the 41 skin biopsies (14.6%) were diagnostic 
of Buruli ulcer (containing acid-fast bacteria (AFB) or 
active necrosis of adipose tissue); 29 (70.7%) were 
indicative of Buruli ulcer (granulomatous changes and 
necrosis, without AFB); and six revealed nonspecific 
inflammation. Three specimens (7%) yielded positive 
cultures. These are the first M. ulceruns isolates reported 
from C&e d’Ivoire. 
Table 2. Comparison of ulcer photographs, Buruli ulcer treatment trial 
Thirty participants who demonstrated compliance 
and returned for follow-up were available for analysis 
for change in ulcer size. Adequate follow-up photo- 
graphs were available for 28 of these 30 patients 
(sample photographs, Figures 1 and 2). The evaluators 
found that 75% of the placebo group patients and 82% 
of the active treatment group patients had improved at 
the 2-month follow-up period; there was no difference 
between treatment groups with regard to outcome as 
judged by the photographs (P=O.51) (Table 2). The dap- 
sone and rifampin group (n=15) experienced a decrease 
in median ulcer size of 14.0 cm2 (range, 0.0-121); 
the placebo group (n=15) experienced a decrease in 
median size of 2.5 cm2 (range, 0.0-81.0) (P=O.O2) 
(Table 3). 
DISCUSSION 
In vitro susceptibility testing and trials in animals have 
provided evidence for activity of several antimycobac- 
terial agents against M. ulceruns. Isolates are susceptible 
in vitro to streptomycin, and this agent inhibited devel- 
opment of lesions in mice when given early in infec- 
tion.18-21 Streptomycin has never been evaluated in 
controlled trials in humans, but it has been used sporad- 
ically in endemic areas with encouraging results.22 How- 
ever, the need for parenteral administration has limited 
the usefulness of streptomycin. Laboratory investiga- 
Grade 
Evaluator 1 Evaluator 2 Combined (P=O.Sl) 
Treatment* Placebo Treatment* Placebo Treatment* Placebo 
Worse 1 0 0 1 1 1 
Unchanged 2 4 2 2 4 6 
Improved 11 10 12 11 23 21 
*Dapsone and rifampin therapy. 
Table 3. Comparison of ulcer sizes, Buruli ulcer treatment trial 
Median Ulcer Size 
At enrollment median (cm2) 
Range (cm2) 
After 1 month median (cm’) 
Range (cm2) 
After 2 months 
Median (cm*) 
Range (cm’) 
Median change in ulcer size 
After 1 month (cm2) 
Range 
After 2 months 
Median Range 
Treatment 
(n=15) 
26.2 
0.25-280 
5.3 
0.0-144.0 
3.0 
0.0-121.0 
-8.0 (increase) 
69.5 to -136.0 
14.0 (decrease) 
(3.8 to -159.0) 
Placebo 
(n=15) 
4.8 
0.25-280 
5.0 
0.0-I 15.0 
1.5 
0.0-81 .O 
1 .O (decrease) 
112.0 to -30.5 
2.5 (decrease) 
78.0 to -35.0 
P-Value 
0.04 
0.54 
0.89 
0.26 
0.02 
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tors have demonstrated susceptibility of M. ulceruns to 
cotrimoxazole by disk and minimum inhibitory concen- 
tration.13 The only therapeutic trial of BU using cotri- 
moxazole, however, was inconclusive because of 
limitations in study design.23 Clofazimine is effective 
against M. ulcerans in mice and appeared promising in a 
pilot study in humans, but a double-blind, placebo-con- 
trolled trial failed to confirm its efficacy.16,24 Rifampin 
is active in vitro and in mice,25j26 but has not been eval- 
uated in a controlled clinical trial. Mycobacterium 
ulcerans is also susceptible to dapsone in vitro and in 
animals,15,20 but this agent also has not been clinically 
evaluated. 
In the present study, most patients showed clinical 
improvement, with or without antibiotic therapy. 
Although a significantly larger decrease in ulcer size 
was associated with antibiotic treatment with dapsone 
and rifampin, no discernible differences in outcome 
were noted between treatment groups, based on evalua- 
tion of photographs by experienced clinicians. This dis- 
crepancy has several possible explanations. First, since 
over three-quarters of the patients in both groups 
showed improvement, the statistical power of the trial 
to demonstrate differences in improvement was limited. 
Second, clinical evaluation was limited to interpretation 
of paired photographs of a single lesion. Since healing 
in one area of a lesion can occur while progression is 
observed elsewhere, and a secondary lesion may arise 
while the primary lesion appears to be healing, some 
misclassification may have occurred. Thirdly, because 
infection may progress in subcutaneous tissue without 
immediate cutaneous mabifestations, clinical evolution 
may be imperfectly reflected by the superficial mor- 
phology of the lesion. Finally, despite high rates of 
improvement at 2 months, it is possible that additional 
beneficial effects of treatment might have been seen 
with a longer treatment and follow-up period; such 
benefits could include fewer relapses and less scarring 
or deformity. 
Measurement of lesion size is a more objective 
criterion and was planned to be the primary study end- 
point. However, differential dropout of patients with 
larger lesions from the placebo group resulted in a 
significant imbalance between the two groups with 
respect to the initial size of the lesions,, with patients in 
the active treatment group having larger initial ulcers. 
Although it is unknown whether larger initial lesions 
are more or less likely to heal spontaneously, it is pos- 
sible that such a difference, rather than a beneficial 
effect of antibiotics, was responsible for the greater 
reduction in median lesion size seen in the antibiotic- 
treated group. Use of photographs to accurately quan- 
tify lesion size provides a practical field tool for a 
clinical trial, but such methodology is not necessary for 
routine clinical evaluation of BU lesions. 
Diagnosis of BU remains largely clinical. To those 
accustomed to seeing BU, especially in endemic areas, 
its clinical diagnosis poses little difficulty; however, for 
newly or sparsely affected regions, better education of 
health care workers may be needed to improve recogni- 
tion of early lesions. Cultures of lesions are infrequently 
positive; the yield of 7% positive cultures from charac- 
teristic lesions in this study is similar to rates reported 
by others.1%4 It is thought that tissue necrosis rapidly 
limits the multiplication of the bacteria, such that cul- 
tures taken more than a few days after the lesions 
ulcerate are less likely to contain organisms. To circum- 
vent the limitations of culture and histologic diagnosis 
in research settings, newer techniques, such as poly- 
merase chain reaction, may be useful in establishing the 
diagnosis of BU.” 
This study did not demonstrate a convincing benefit 
of therapy of BU with rifampin and dapsone; neverthe- 
less the results indicate a need for further investigation 
of this and other antimycobacterial regimens for the 
treatment of BU.28 This pilot study indicates that such 
trials are feasible. A substantial number of participants 
were enrolled in a short time, and 75% of the partici- 
pants demonstrated compliance with the regimen over 
a 2-month period. No serious complications of the 
antibiotic regimen were observed. However, patient 
adherence was difficult to ensure, and longer follow-up 
is needed. As frequency of BU continues to increase in 
West Africa and elsewhere,29 development of inexpen- 
sive, effective, and well-tolerated treatment regimens 
that can be used in rural areas with limited resources 
becomes an increasingly important public health 
priority. 
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